NCT00118755View on ClinicalTrials.gov

A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

435

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

April 30, 2009

Conditions

Colorectal Cancer

Interventions

DRUG

capecitabine

850 mg/m\^2 po bid on Days 1-14 of each 3-week cycle

DRUG

Oxaliplatin

130 mg/m\^2 IV on Day 1 of each 3-week cycle

DRUG

bevacizumab

7.5 mg/kg IV on Day 1 of each 3-week cycle

DRUG

capecitabine

1500 mg/m\^2 po bid on Days 1-7 of each 2-week cycle

DRUG

Oxaliplatin

85 mg/m\^2 IV on Day 1 of each 2-week cycle

DRUG

bevacizumab

5 mg/kg IV on Day 1 of each 2-week cycle

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT00118755 - A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter